Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
Eli Lilly: A Strong Buy Amidst Obesity Treatment Market Dominance and Expanding Pipeline
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
Investor's Business Daily on MSN3h
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.
ConsumerAffairs23h
FTC alleges Caremark Rx, Express Scripts, Optum Rx inflated insulin prices
The Federal Trade Commission is suing the three largest prescription drug benefit managers (PBMs) for allegedly driving up ...
BioWorld19h
Zevra’s Miplyffa wins first FDA approval in Niemann-Pick type C
Following the recent recommendation of its advisory committee, the U.S. FDA gave the nod to Zevra Therapeutics Inc.’s ...
BioWorld1h
FO-4-15, an anti-AD candidate with reduced neurotoxicity and enhanced neuroprotective effects
Researchers from the Chinese Academy of Medical Sciences reported the discovery of the 1,2,4-oxadiazole derivative FO-4-15 for the treatment of Alzheimer’s disease (AD).